Tirzepatide approved to treat sleep apnoea in patients with obesity
Drug maker Eli Lilly said it was the first Australian-registered OSA treatment.
Tirzepatide is now TGA registered to treat moderate to severe obstructive sleep apnoea in patients with obesity.
Drug maker Eli Lilly says tirzepatide (Mounjaro) is the first drug in Australia indicated for obstructive sleep apnoea (OSA) in any population.
It would provide patients with an easier alternative to CPAP or bariatric surgery, said Melbourne sleep physician Professor Garun Hamilton.
“This is something we have been watching closely,” said Professor Hamilton, president of the Australasian Sleep Association.
